Moderna Inc to Discuss New Interim Clinical Data About mRNA Vaccine Against COVID-19 - Conference Call Transcript
Good afternoon and welcome to Moderna's conference call. (Operator Instructions) Please be advised that the call is being recorded.
At this time, I'd like to turn the call over to Lavina Talukdar, Head, Investor Relations at Moderna. Please proceed.
Thank you, Gigi. Hello, everyone. Hope you are all well, and thank you for joining us this afternoon or late night, depending on where you're dialing in from. On today's conference call, we will discuss our Phase I interim results from the older adult cohorts for mRNA-1273, our vaccine against COVID-19. You can access the press release issued today as well as the slides that we'll be reviewing by going to the Investors section of our website.
Speaking on today's call are Stéphane Bancel, our Chief Executive Officer; Tal Zaks, our Chief Medical Officer; Juan Andres, our Chief Technical and Manufacturing Officer; and David Meline, our Chief Financial Officer.
Before we begin, note that this conference call will include forward-looking statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |